Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Middle East Conflict Impacts Australia and New Zealand Businesses 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
SAN DIEGO, May 03, 2018 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Thursday, May 10, 2018 at 5:00 p.m. ET to report its first quarter 2018 financial results and provide a corporate update.
In order to participate in the conference call, please dial 877-303-6235 (domestic) or 631-291-4837 (international) and refer to conference ID 5592629. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The Company's hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cell lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Fate Therapeutics is headquartered in San Diego, CA.
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
[email protected]
